Noxxon to present data from NoxA12Keytruda combo trial at Esmo ImmunoOncology congress

Noxxon to present data from Nox─A12/Keytruda combo trial at Esmo Immuno─Oncology congress

Noxxon Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumour microenvironment (TME), announced the details of its participation at the ESMO Immuno─Oncology

More From BioPortfolio on "Noxxon to present data from Nox─A12/Keytruda combo trial at Esmo Immuno─Oncology congress"